The drug industry's new five-year pricing deal in the U.K. effectively imposes steep price cuts on existing branded drugs but exempts new drugs from rebates. The jury is out on whether the scheme will promote innovation.

Previous Pharmaceutical Price Regulation Scheme (PPRS) agreements saw industry provide small price cuts on branded drugs in exchange for the ability to set any price - known as free pricing - at launch.